| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Biologics | Dermatologic System |
Recent Updates
Recently added Catalysts
Azitra Inc$0.14
-0.01 (-4.44%)
D 25Pipeline Score Richly Valued Pharma · Clinical
Market Cap
3.30 M
EPS
-2.31
P/E Ratio
-
Value Trade
60.10 K
SEC Financials
Q1 2026Dilution Risk
40%R&D Expenses
1.56 M
Operating CF
-2.48 M
Total Assets
12.13 M
Total Liabilities
1.65 M
Equity
10.48 M
D/E Ratio
12,345
7.88 %
Week
-4.54 %
1 Month
13.28 %
3 Month
-34.52 %
6 Month
-99.98 %
5 Year
-99.98 %
All Time
Cash Data
Cash Position
10.05 M
Monthly Burn
826.00 K
Runway
10.5 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
1.15 M
52 Week Range
0.10 - 2.40
% held by Insiders
25.11 %
% held by Institutions
42.12 %
Enterprise Value
-6.31 M
Total Shares
15.89 M
Short %
1.82 %
Float Shares
15.32 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Azitra Inc
156Total events
11Upcoming
22Tier-1 (high impact)
2023 – 2027Coverage
Upcoming catalysts 11
Apr 1, 2027
T2Timing Guidance
Deadline to regain compliance with NYSE American continued listing standards
Event history 145
Jun 23, 2026
Jun 17, 2026
▲Enrollment UpdateATR-04Trial
Continued enrollment and addition of MD Anderson Cancer Center as clinical site
EGFR inhibitor-associated rashsource ↗
Jun 17, 2026
▼Enrollment PausedATR-12Trial
Pause further enrollment in ATR-12 trial to conserve capital
Netherton syndromesource ↗
May 13, 2026
●Oral PresentationATR-01Presentation
ATR-01 preclinical data presented at ASGCT 2026
Ichthyosis Vulgarissource ↗
Apr 28, 2026
◆Poster PresentationATR-01Presentation
Poster presentation at ASGCT 2026 highlighting preclinical data for ATR01-616
ichthyosis vulgarissource ↗
Apr 21, 2026
▲Patent GrantedATR-12IP / Competition
U.S. Patent 12,606,610 B2 issued for ATR-12
Netherton syndromesource ↗
Mar 19, 2026
▼Equity OfferingCorporate
Pricing of private placement financing of up to approximately $31.4 million
Mar 5, 2026
Mar 2, 2026
Mar 2026
▲Equity OfferingCorporate
Raised $10.5 million with up to $21 million additional through warrant exercise
Drug Pipeline Intelligence
D25
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.1x
rNPV / MCap Top 26%
Micro Cap (rank 675 of 911)
Percentile RankAzitra Inc faces pipeline headwinds (25/100), with $16M risk-adjusted pipeline value, led by ATR04-484 in EGFR Inhibitor-associated Rash (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATR04-484 Small molecule | EGFR Inhibitor-associated Rash | Phase 1 | NCT06830863 | 7% | $16M | RECRUITING | 32 | STALLED | B (63) | Feb 15, 2027 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ATR-12 | Netherton syndrome | Phase 1b | 2025-09-04 | Azitra's Phase 1b clinical trial of ATR-12 for Netherton syndrome reported promising safety results, indicating a favorable safety profile for the treatment in adult patients, although specific efficacy metrics were not disclosed in the announcement. Read More | Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference Read More | |
ATR-12 | Netherton syndrome | Phase 1b | 2025-09-04 | Azitra's Phase 1b clinical trial of ATR-12 for Netherton syndrome reported promising safety results, indicating a favorable safety profile for the treatment in adult patients, although specific efficacy metrics were not disclosed in the announcement. Read More | Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference Read More | |
ATR-12 | Netherton syndrome | Phase 1b | 2025-09-04 | Azitra's Phase 1b clinical trial of ATR-12 for Netherton syndrome reported promising safety results, indicating a favorable safety profile for the treatment in adult patients, although specific efficacy metrics were not disclosed in the announcement. Read More | Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AZTR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AZTR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AZTR▲ +10.3%on this news
Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
Azitra, Inc. has announced a strategic reorientation aimed at growth, highlighted in a letter from CEO Francisco Salva. The company plans to leverage advancements in synthetic biology and artificial intelligence to enhance its product pipeline, particularly through initiatives like ATR-COSF that target the cosmetic ingredient market. The successful financing in March 2026 raised $10.5 million, enabling these opportunities while also posing risks due to paused clinical trials. Azitra aims to create value for shareholders by exploring broader applications in biotechnology products and recombinant proteins.
Read more →AZTR▼ -7%on this newsshared move
Azitra, Inc. to Present at 2026 BIO International Convention
Azitra, Inc. will present its recent developments at the 2026 BIO International Convention in San Diego, where Travis Whitfill, Ph.D., is scheduled to give a presentation. The highlights will include advancements in Azitra's pipeline, particularly their protein and peptide technologies for the cosmetic market and the clinical programs for Netherton syndrome and EGFR inhibitor associated rash. The company aims to showcase its innovative therapies and secure potential investment and partnership opportunities during the event.
Read more →AZTRAzitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
Azitra, Inc. announced the adjournment of its 2026 Annual Meeting due to insufficient shareholder representation to meet quorum requirements. Originally scheduled for June 4, 2026, the meeting will be reconvened on June 15, 2026. Shareholders are urged to submit their voting proxies prior to the reconvened meeting. The company specializes in innovative therapies for precision dermatology, including treatments for rare skin conditions.
Read more →AZTRAzitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting
Azitra, Inc. announced its intention to adjourn the 2026 Annual Meeting of stockholders originally scheduled for June 4, 2026, reconvening it on June 15, 2026. This decision comes due to a minor administrative delay in mailing proxy materials, allowing stockholders additional time to submit their votes. The meeting will continue to be held virtually, facilitating participation from stockholders who can engage through a live webcast. The proposals at the reconvened meeting will remain unchanged from the original agenda.
Read more →AZTRAzitra, Inc. Announces Q1 2026 Results and Provides Business Updates
Azitra, Inc. reported strong Q1 2026 results, highlighting advancements in its clinical trials and the launch of a new cosmeceutical initiative. The company has expanded its Phase 1/2 trial for ATR-04 by partnering with MD Anderson Cancer Center. Additionally, Azitra received a new patent for ATR-12, which is in a Phase 1b trial for Netherton syndrome, enhancing its market position.
Read more →AZTRAzitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program
Azitra, Inc. has announced the issuance of a new U.S. patent for its lead product candidate, ATR-12, which is currently undergoing a Phase 1b clinical trial for Netherton syndrome. The patent provides broad protections for the engineered strain of S. epidermidis that expresses a fragment of the human LEKTI protein. This development is significant as Netherton syndrome currently has no approved treatments, highlighting the potential impact of ATR-12 on patient care.
Read more →AZTR▲ +11.1%on this news
Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris
Azitra, Inc. presented new preclinical data for its ATR-01 program at ASGCT 2026, demonstrating its potential to treat ichthyosis vulgaris by delivering functional filaggrin into the skin. The engineered biotherapeutic candidate ATR01-616 showed significant efficacy in reducing transepidermal water loss and restoring skin barrier function. The findings support the program's advancement toward clinical trials.
Read more →AZTR▲ +28.8%on this news· ran to +107% by day 1
Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million
Azitra, Inc. has announced a private placement financing agreement to raise up to approximately $31.4 million, comprising $10.5 million in initial funding and an additional $20.9 million contingent upon the exercise of warrants by investors. The funds are intended to support the development of innovative protein and peptide technologies for the cosmeceutical market, leveraging Azitra's microbial genetic engineering platform. Notably, the financing involves several institutional investors and company insiders. The transaction is subject to customary closing conditions, including stockholder approval.
Read more →AZTRAzitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement
Azitra, Inc. has received a notice of non-compliance from the NYSE American, indicating it does not meet the required stockholders' equity standards. The company reported losses over the past fiscal years, prompting this action from the Exchange. Azitra submitted a plan to regain compliance, which has been accepted, and it has until April 1, 2027, to meet these requirements. The notice has no immediate effect on trading but highlights concerns about the company's financial viability as indicated by an auditor's substantial doubt regarding its ability to continue operations.
Read more →AZTRAzitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders
Azitra, Inc. has announced the cancellation of its special meeting of stockholders originally scheduled for February 6, 2026, which was adjourned due to insufficient quorum. The meeting was rescheduled for March 6, 2026. Azitra is focused on developing therapies for precision dermatology, including treatments for Netherton syndrome and EGFR inhibitor-associated rash.
Read more →AZTR▼ -6.1%on this newsshared move
Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates
Azitra, Inc. reported its financial results for FY 2025, highlighting significant advancements in its clinical trials, particularly for ATR-04 and ATR-12. The company received positive feedback at the ASCO Annual Meeting regarding its innovative therapies targeting dermatological conditions. Looking ahead, Azitra anticipates key milestones in 2026, including topline data from ongoing studies.
Read more →AZTRAzitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash
Azitra, Inc. has announced the inclusion of MD Anderson Cancer Center as a clinical site for its Phase 1/2 trial of ATR-04, a treatment for EGFRi-associated skin rash. This expansion is expected to accelerate patient enrollment and treatment milestones. The trial evaluates the safety and tolerability of ATR04-484, a live biotherapeutic product candidate designed to mitigate skin toxicity in cancer patients. The FDA has granted Fast Track designation to ATR-04, highlighting its potential impact on patient care.
Read more →AZTR▲ +7.2%on this newsshared move
Azitra, Inc. to Present at BIO Investment & Growth Summit
Azitra, Inc. has announced its participation in the BIO Investment & Growth Summit scheduled for March 2-3, 2026. The presentation will cover updates on its clinical pipeline, including therapy candidates ATR-12 and ATR-04, which focus on dermatological conditions with significant unmet needs. Azitra's management will also engage in one-on-one meetings with investors to discuss the company's growth strategy and recent milestones. Key aspects of its proprietary platform and the implications of their ongoing clinical trials will be highlighted during this event.
Read more →AZTRAzitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
Azitra, Inc. has announced the adjournment of its Special Meeting originally scheduled for February 6, 2026, due to a lack of quorum. The meeting will reconvene on March 6, 2026, to solicit additional votes on key proposals. Stockholders are encouraged to participate and vote ahead of the reconvened meeting.
Read more →AZTR▲ +6.9%on this news
Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
Azitra, Inc. will present at the Biotech Showcase in San Francisco from January 12-14, 2026. The company aims to highlight its clinical development strategy and recent achievements. Azitra's lead program, ATR-12, targets Netherton syndrome, while ATR-04 addresses EGFR inhibitor-associated skin toxicity. Both programs are supported by a proprietary platform of engineered proteins.
Read more →AZTRAzitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
Azitra, Inc. has received approval from NYSE American for its compliance plan to meet listing standards after previously being notified of non-compliance. The company must regain compliance by April 1, 2027, or face potential delisting. Azitra continues to explore funding options while maintaining its listing during this period.
Read more →AZTRAzitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules
Azitra, Inc. announced a $1.5 million private placement of common stock and warrants at a premium price. The offering involves 4,687,500 shares and is expected to close on November 25, 2025. The funds will support Azitra's clinical programs, including treatments for Netherton syndrome and EGFRi associated skin toxicity.
Read more →AZTR▼ -14.6%on this news
Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates
Azitra, Inc. reported its Q3 2025 financial results and highlighted significant advancements in its clinical programs. The company initiated dosing in a Phase 1/2 trial for ATR-04, targeting skin toxicity in oncology patients. Positive preclinical data for ATR-01 was presented, and the company remains optimistic about its lead program, ATR-12, for Netherton syndrome. Despite financial losses, Azitra is focused on its innovative therapies for precision dermatology.
Read more →AZTR▼ -10.2%on this newsshared move
Azitra, Inc. Addresses False Report Regarding Sale of Securities
Azitra, Inc. has addressed a false report claiming it priced a $44 million registered direct offering. The company urges stakeholders to rely on official communications and is investigating the source of the misinformation. Azitra is focused on developing therapies for precision dermatology, including its lead program, ATR-12, for Netherton syndrome.
Read more →AZTRAzitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris
Azitra, Inc. announced positive preclinical results for its ATR-01 program, aimed at treating ichthyosis vulgaris. The data, to be presented at BIO-Europe, shows effective delivery of functional filaggrin through skin models. The company is optimistic about advancing to first-in-human trials in 2026, addressing a significant unmet need for patients.
Read more →AZTRAzitra to Participate in Dermatologic Rare Disease Panel at Maxim Growth Summit
Azitra, Inc. will have its COO, Travis Whitfill, participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit in New York City. The panel will cover Netherton syndrome and Recessive Epidermolysis Bullosa, with Azitra's ATR-12 program currently in Phase 1b trials for Netherton syndrome. The company aims to showcase its clinical strategies and achievements during the event.
Read more →AZTRAzitra Receives Notice of Non-Compliance from NYSE American
Azitra, Inc. has received a notice of non-compliance from NYSE American due to insufficient stockholders' equity. The company is required to submit a compliance plan by October 31, 2025, to address this issue. Despite the notice, there is no immediate impact on trading or business operations. Azitra is actively exploring funding options to meet the exchange's requirements.
Read more →AZTR▼ -9.8%on this news· ran to -20% by day 3
Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Azitra, Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation will cover updates on their clinical pipeline, including positive safety results for the ATR-12 program in Netherton syndrome and the initiation of the ATR-04 program trial. The company aims to engage with investors and partners during the event.
Read more →AZTR▲ +35.9%on this news
Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash
Azitra, Inc. has initiated the dosing of the first patient in its Phase 1/2 clinical trial for ATR04-484, aimed at treating EGFR inhibitor-associated rash. This milestone is significant as the FDA has granted Fast Track designation for this treatment, which addresses a pressing need for oncology patients. The trial will evaluate the safety and efficacy of the biotherapeutic product in managing dermatologic toxicities linked to cancer therapies.
Read more →AZTR▼ -7.6%on this news
Azitra, Inc. Announces Reverse Stock Split
Azitra, Inc. has announced a reverse stock split at a ratio of 1-for-6.66, effective August 21, 2025. This decision follows stockholder approval and aims to reduce the number of issued shares significantly. The company will continue trading under the ticker AZTR, and stockholders will receive cash for any fractional shares resulting from the split.
Read more →AZTRAzitra, Inc. Announces Q2 2025 Results and Provides Business Updates
Azitra, Inc. (AZTR) released its Q2 2025 results, showcasing significant progress in its clinical pipeline. The company reported that it has reached 50% enrollment in its Phase 1b clinical trial for ATR-12, aimed at treating Netherton syndrome, a severe skin condition. Additionally, Azitra announced the acceptance of a poster presentation for the ATR-04 program at the upcoming ASCO Annual Meeting. Despite a net loss of $2.9 million for the quarter, the company highlighted its strategic partnership with Alumni Capital LP to secure funding for future developments.
Read more →AZTRAZITRA, INC. 21 Business Park Drive Branford, Connecticut 06405 (203) 646-6446 SUPPLEMENT TO PROXY STATEMENT RELATED TO ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 23, 2025 This proxy statement supplement, dated
Azitra, Inc. has issued a supplement to its proxy statement for the Annual Meeting of Stockholders scheduled for June 23, 2025. This supplement updates the voting standard for Proposal 2, which pertains to an amendment to increase the authorized shares of common stock from 100 million to 200 million. The change follows the recent DGCL Amendment, which modified the approval requirements for such actions. The company encourages stockholders to review both the Proxy Statement and this Supplement before voting.
Read more →AZTRAzitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome
Azitra, Inc. reported positive safety data from the Phase 1b trial of its live biotherapeutic candidate, ATR12-351, aimed at treating Netherton syndrome. The trial, which is 50% enrolled with six patients already dosed, showed that ATR12-351 has been generally safe and well-tolerated. Mild to moderate application site reactions were noted but no severe adverse events occurred. The ongoing trial is crucial for assessing the viability of ATR12-351 as a treatment option for this rare and severe skin disease.
Read more →AZTRAzitra, Inc. Announces Presentation at the 2025 BIO International Convention
Azitra, Inc. has announced its participation in the 2025 BIO International Convention, where it will present advancements in its pipeline therapies, including ATR-12 and ATR-04. These programs target Netherton syndrome and EGFRi-associated dermal toxicity, respectively. The convention will provide a platform for Azitra to showcase its clinical development strategy and engage with investors. Notably, ATR-04 has received Fast Track designation from the FDA due to the impact of its associated rash treatment.
Read more →AZTRAzitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash
Azitra, Inc. announced it will present a Phase 1/2 clinical trial of ATR04-484 for treating EGFRi-associated rash at ASCO 2025. This innovative therapy involves a novel strain of Staphylococcus epidermidis. The clinical trial aims to address skin toxicities faced by patients undergoing EGFR inhibitor treatments. The presentation highlights Azitra's commitment to improving patient quality of life in oncology settings and showcases the potential of ATR04-484.
Read more →AZTRAzitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash
Azitra, Inc. will present an abstract concerning its Phase 1/2 clinical trial of ATR04-484, aimed at treating EGFR inhibitor-associated rash, at the ASGCT Annual Meeting in May 2025. Led by Dr. Mary Spellman, the presentation highlights the clinical development of this therapy, which has received Fast Track designation from the FDA. Azitra anticipates initiating patient dosing shortly, though the company acknowledges risks associated with forward-looking statements that could impact timelines and outcomes.
Read more →AZTRAzitra, Inc. Announces Q1 2025 Results and Provides Business Updates
Azitra, Inc. reported its financial results for Q1 2025 and highlighted significant business developments. The company announced a partnership with Alumni Capital LP for funding and plans to provide initial safety data for its ATR-12 program targeting Netherton syndrome. Additionally, Azitra aims to commence patient dosing for its ATR-04 program aimed at treating EGFRi-associated rash within the year. Despite a reported increase in net loss and operational expenses, the company is poised for several key milestones in 2025.
Read more →AZTRAzitra, Inc. to Present ATR-04 Program Update at ASCO 2025
Azitra, Inc. has announced that their ATR-04 program, aimed at treating EGFR inhibitor-associated rash, will be presented at the ASCO 2025 Annual Meeting. The company plans to dose its first patient in a Phase 1/2 trial in the first half of 2025. ATR04-484, a live biotherapeutic product candidate, aims to address the dermatologic complications often linked with EGFR inhibitors. Azitra has received Fast Track designation from the FDA for this program, and further details will be presented at the conference in Chicago.
Read more →AZTRAzitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline
Azitra, Inc. has announced a share purchase agreement with Alumni Capital LP to fund its clinical pipeline with up to $20 million. This partnership aims to support the development of therapies for rare skin disorders, including Netherton Syndrome. The agreement allows Azitra to minimize shareholder dilution while controlling the timing of common stock sales. However, the company faces several risks, including successful clinical trial outcomes and regulatory approvals.
Read more →AZTRAzitra to Present at Microbiome Times Partnering Forum
Azitra, Inc. announced that its COO, Travis Whitfill, will present at the Microbiome Times Partnering Forum on March 19, 2025, in Brussels, Belgium. The presentation will focus on ATR-12, an engineered strain of S. epidermidis for treating Netherton syndrome, a rare skin disease with no approved treatments. Azitra is also planning one-on-one meetings with investors and partners to outline its business strategy and milestones. The company has received Fast Track designation from the FDA for another product aimed at EGFR inhibitor associated rash.
Read more →AZTRAzitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates
Azitra, Inc. reported its full year 2024 financial results, highlighting the initiation of a Phase 1b clinical trial for ATR-12, aimed at treating Netherton syndrome. The company also received FDA clearance and Fast Track designation for its product ATR-04, targeting EGFRi-associated dermal toxicity. Despite these advancements, Azitra incurred a net loss of $9.0 million in 2024, an increase from the previous year, alongside minimal revenue generation. The company continues to develop its innovative pipeline of dermatological therapies utilizing engineered proteins.
Read more →AZTR▲ +16.3%on this news
Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock
Azitra, Inc. has announced a registered direct offering to institutional investors, totaling approximately $930,000 through the sale of 3,339,300 shares at $0.2785 each. The offering is expected to close on February 5, 2025, and the proceeds will be utilized for working capital and general corporate purposes. Azitra is focused on developing innovative therapeutics for precision dermatology and is advancing its lead product, ATR-12, for Netherton syndrome, alongside ATR-04 for EGFR inhibitor-associated rash.
Read more →AZTR▲ +15.1%on this news· ran to +60% by day 3shared move
Azitra, Inc. to Present at the BIO CEO & Investor Conference
Azitra, Inc. announced its participation in the BIO CEO & Investor Conference on February 10-11, 2025, in New York City. The company will showcase its business and clinical strategies along with recent achievements, focusing on its lead product ATR-12 designed for Netherton syndrome and ATR-04 for EGFR inhibitor associated rash. Azitra is in the clinical stages of developing these therapies and has received FDA Fast Track designation for ATR-04. The presentation will be led by the COO, Travis Whitfill, who will also engage in one-on-one meetings with investors during the conference.
Read more →AZTR▼ -6.6%on this news
Azitra, Inc. to Present at The Microcap Conference
Azitra, Inc. has announced its participation in The Microcap Conference 2025, scheduled for January 29, where CEO Francisco Salva will present the company's strategic plans. The focus of Azitra is on developing therapies for precision dermatology, especially for conditions like Netherton syndrome and EGFR inhibitor-associated rash. The conference will also facilitate one-on-one meetings between Azitra's management and investors. The company's lead product, ATR-12, is currently undergoing a Phase 1b clinical trial, while ATR-04 has received Fast Track designation from the FDA.
Read more →AZTR▼ -39%on this news
Azitra Announces Pricing of $1.5 Million Public Offering of Common Stock
Azitra, Inc. has announced the pricing of a public offering of 4,857,780 shares at $0.30 each, aiming to raise approximately $1.5 million before expenses. The offering is expected to close on January 16, 2025, pending customary closing conditions. The funds raised will be used for working capital and general corporate purposes. Azitra is focused on developing therapies for precision dermatology, with its lead product ATR-12 being evaluated for treating Netherton syndrome and ATR-04 for EGFR inhibitor-associated rash.
Read more →AZTR▼ -26.7%on this news· ran to -57% by day 3shared move
Azitra Announces Proposed Public Offering of Common Stock
Azitra, Inc. has announced a proposed public offering of shares of its common stock, primarily for working capital and corporate purposes. The offering is conducted under an effective shelf registration filed with the SEC. Azitra is known for its focus on therapies for precision dermatology, specifically its lead product, ATR-12, developed for Netherton syndrome and ATR-04 for EGFR inhibitor associated rash. The completion and size of the offering depend on market conditions and other factors.
Read more →AZTR▲ +5%on this news
Azitra, Inc. to Present at Biotech Showcase 2025 Alongside the J.P. Morgan Annual Healthcare Conference
Azitra, Inc. will present at the upcoming Biotech Showcase 2025 in San Francisco. The presentation, led by COO Travis Whitfill, will focus on the company's innovative therapies for precision dermatology, including ATR-12 for Netherton syndrome. Azitra is also advancing ATR-04 for EGFR inhibitor-associated rash and has received Fast Track designation from the FDA. The event will provide opportunities for one-on-one meetings with investors to discuss clinical developments and future milestones.
Read more →AZTRAzitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates
Azitra, Inc., a clinical-stage biopharmaceutical company, reported its financial results for Q3 2024, revealing significant progress in its clinical pipeline. The company dosed its first patient in a trial for Netherton syndrome with ATR-12 and received IND clearance and Fast Track designation for ATR-04 aimed at treating skin rash associated with EGFR inhibitors. Financially, Azitra had a net loss of $1.0 million for the quarter, a decrease from $1.9 million a year prior, but did not report any service revenue. The company remains focused on executing its clinical trials and maximizing shareholder value.
Read more →AZTRAzitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates BRANFORD, Conn. - Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies f
Azitra, Inc. reported its Q2 2024 financial results, showcasing a follow-on offering that raised $10 million. The company also highlighted positive preclinical data for its investigational drugs ATR-04 and ATR-12, with plans to dose the first Netherton syndrome patient soon. Financially, Azitra experienced a net loss of $2.6 million, down from $5.1 million a year prior, but service revenue fell sharply compared to 2023. The firm is optimistic about upcoming clinical milestones and expanding its product pipeline.
Read more →AZTR▲ +206.8%on this news
Azitra, Inc. Announces Pricing of $10.0 Million Public Offering
Azitra, Inc. has announced the pricing of a public offering aimed at raising approximately $10.0 million. The offering includes 6,665,000 shares of common stock and Class A warrants for an additional 13,330,000 shares, priced at $1.50 each. Proceeds will be used for working capital and general corporate purposes. The closing of this offering is expected around July 25, 2024, pending customary conditions. Azitra focuses on developing dermatological therapies using engineered proteins and a proprietary microbial library.
Read more →AZTRAzitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates BRANFORD, Conn. - Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies f
Azitra, Inc. reported its Q1 2024 financial results, highlighting advancements in its clinical programs, including ATR-12 and ATR-04. The company noted significant progress in securing clinical sites for ATR-12's Phase 1b trial targeting Netherton syndrome, with expectations for initial safety data later this year. Despite the positive clinical advancements, Azitra reported a net loss of $2.9 million, reflecting an increase from the previous year, alongside a drop in service revenue. The company aims to submit an IND for ATR-04 by mid-2024, bolstered by a recent public offering that secured $5.0 million in funding.
Read more →AZTRAzitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates BRANFORD, Conn.-(BUSINESS WIRE)-Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing i
Azitra, Inc. announced its full-year financial results for 2023, highlighting key business developments, including financial achievements and clinical progress. The company successfully completed an IPO and a follow-on offering, raising a total of $12.5 million. They obtained IND clearance for ATR-12, which is set to enter a Phase 1b clinical trial for Netherton syndrome, and advanced their program ATR-04 into IND-enabling studies. The company reported a net loss of $11.3 million for 2023, reflecting ongoing financial challenges amid a strong focus on innovation in precision dermatology.
Read more →AZTRAzitra, Inc. Announces Pricing of Public Offering
Azitra, Inc. has announced the pricing of a public offering for 16,667,000 shares of common stock, priced at $0.30 per share, aiming for gross proceeds of roughly $5 million. The funds raised will be allocated towards clinical trials, product development, and general corporate purposes. The offering is expected to close on February 16, 2024, pending customary closing conditions. Additionally, an option for underwriters to purchase an extra 2,500,000 shares has been granted for over-allotments.
Read more →AZTRAzitra, Inc. Announces Third Quarter 2023 Financial Results and Business Updates BRANFORD, Conn. - Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies
Azitra, Inc. reported its financial results for Q3 2023, indicating significant progress in its pipeline, particularly with ATR-12 for Netherton syndrome. The company has hired a clinical research organization for the ATR-12 clinical trial and is preparing for patient recruitment. Azitra's service revenue saw a notable increase, although the company still faced a net loss of $1.9 million for the quarter. Upcoming milestones include enrolling patients and submitting an IND for ATR-04, with ongoing collaboration with Bayer.
Read more →AZTRAzitra to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Azitra, Inc. will present at the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023. COO Travis Whitfill will offer an overview of the company's innovative approach in precision dermatology, leveraging engineered proteins and a proprietary microbial library. An on-demand presentation will be available starting September 11, with an archive accessible for 90 days. The conference represents a key opportunity for investor engagement and showcasing Azitra's developments.
Read more →AZTRAzitra, Inc. Announces Second Quarter 2023 Financial Results and Business Updates
Azitra, Inc. announced its financial results for the second quarter of 2023, highlighting a net loss of $4.4 million compared to $1.9 million in the same period last year. The company successfully completed an IPO in June 2023, raising $7.5 million, and announced the initiation of a Phase 1b clinical trial for its lead product, ATR-12, targeting Netherton syndrome. The report also included key management appointments aimed at strengthening its leadership team, despite an overall increase in operating expenses.
Read more →AZTRAzitra Adds Biotech Leaders Barbara Ryan and John Schroer to Its Board of Directors
Azitra, Inc. has announced the expansion of its board of directors with the appointments of Barbara Ryan and John Schroer. Both candidates are seasoned professionals in the biotech industry, bringing a wealth of knowledge in corporate strategy and capital markets. This move is aimed at bolstering Azitra's capabilities as it progresses through clinical trials and partnerships, notably with Bayer. The company is focused on developing innovative precision dermatology therapies, leveraging its proprietary microbial library and AI technologies.
Read more →AZTRAzitra, Inc. Appoints Travis Whitfill as Chief Operating Officer
Azitra, Inc. has appointed Travis Whitfill as Chief Operating Officer, who is returning to the company after nearly ten years in biotech venture capital. Whitfill, a cofounder of Azitra, is expected to leverage his extensive experience in biotechnology and drug development, particularly as the company prepares to begin patient dosing for ATR-12 targeting Netherton syndrome. This strategic leadership move coincides with Azitra's broader focus on creating novel therapies using engineered proteins for precision dermatology, supported by their advanced microbial library and AI technologies.
Read more →AZTR▲ +9.6%on this news
Azitra, Inc. Announces Closing of Initial Public Offering
Azitra, Inc. has successfully announced the closing of its initial public offering, offering 1,500,000 shares at $5.00 each and raising a total of $7.5 million. The funds from the IPO will be allocated towards clinical trials, product development, and general corporate purposes. The company focuses on innovative therapies for precision dermatology utilizing engineered proteins and a unique microbial library. A 45-day option for underwriters to purchase additional shares is also part of this offering.
Read more →AZTRAzitra, Inc. Announces Pricing of Initial Public Offering
Azitra, Inc. has announced the pricing of its initial public offering (IPO), offering 1,500,000 shares of common stock at $5.00 each, aiming to raise $7,500,000. The shares are set to commence trading on the NYSE American under the ticker symbol 'AZTR' on June 16, 2023, with the offering expected to close on June 21, 2023. The funds will be allocated to clinical trials, research and development, and general corporate purposes. ThinkEquity is acting as the sole book-running manager for this offering.
Read more →AZTRAzitra to Present at the Biotech Showcase Annual Conference on January 8, 2018
FARMINGTON, CT, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Azitra Inc. today announced that Richard Andrews, President and Chief Executive Officer, is scheduled to present at Biotech Showcase™ 2018 taking place on January 8-10, 2018 at the Hilton San Francisco Union Square, San Francisco,
Read more →Competitive Position
How AZTR ranks across every disease it competes inCompetitive Position is a premium feature
See how AZTR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial